BASKING RIDGE, N.J. and SHIRLEY, N.Y., May 6, 2021 /PRNewswire/ -- Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug ...

First and only high-dose intravenous iron for iron deficiency anemia of various etiologies SHIRLEY, N.Y.--(BUSINESS WIRE)--American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a ...

Credit: American Regent. The approval was based on data from the randomized, double-blind, placebo-controlled phase 4 CONFIRM-HF trial. The Food and Drug Administration (FDA) has approved Injectafer ® ...

Injectafer (ferric carboxymaltose) is a brand-name drug that’s prescribed for iron deficiency anemia in adults and some children. Injectafer comes as a liquid solution that’s given by a healthcare ...

The US Food and Drug Administration (FDA) has approved ferric carboxymaltose injection (Injectafer) for the treatment of iron-deficiency anemia (IDA) in adults who either cannot tolerate or have not ...

Please provide your email address to receive an email when new articles are posted on . Daiichi Sankyo Inc. and American Regent Inc. announced FDA approval of Injectafer, a ferric carboxymaltose ...

The US Food and Drug Administration (FDA) has expanded the indication for ferric carboxymaltose injection (Injectafer, Daiichi Sankyo/American Regent) to include treatment of iron deficiency in adults ...

More than 6 million U.S. adults — most over the age of 60 — are living with heart failure.¹If you or someone you care about has heart failure, you may already know it’s a chronic but manageable ...